Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Seeking Alpha5/12/2026Neutral
HBIO
Harvard Bioscience IncNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$28.32M
P/E Ratio
—
EPS
$-2.03
Beta
1.50
52W High
$9.40
52W Low
$3.75
50-Day MA
$6.12
200-Day MA
$5.79
Dividend Yield
—
Profit Margin
-11.40%
Forward P/E
15.06
PEG Ratio
1.31
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Fundamentals
| Revenue (TTM) | $85.53M |
| Gross Profit (TTM) | $49.97M |
| EBITDA | $7.82M |
| Operating Margin | -4.52% |
| Return on Equity | -78.60% |
| Return on Assets | 1.73% |
| Revenue/Share (TTM) | $19.20 |
| Book Value | $2.23 |
| Price-to-Book | 2.80 |
| Price-to-Sales (TTM) | 0.33 |
| EV/Revenue | 0.762 |
| EV/EBITDA | 44.85 |
| Quarterly Earnings Growth (YoY) | -80.30% |
| Quarterly Revenue Growth (YoY) | -4.70% |
| Shares Outstanding | $4.51M |
| Float | $3.50M |
| % Insiders | 9.48% |
| % Institutions | 41.59% |
Historical Volatility
HV 10-Day
44.57%
HV 20-Day
54.26%
HV 30-Day
54.07%
HV 60-Day
86.96%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($6.00 target)
1
Strong Buy1
HoldLatest News
Harvard Bioscience Announces First Quarter 2026 Financial Results
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.
GlobeNewsWire5/12/2026Neutral
Harvard Bioscience to Participate in Upcoming Investor Conferences
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.
GlobeNewsWire5/7/2026Neutral
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
GlobeNewsWire4/28/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026